Overview of Diatab

Quick Facts

Property	Description
Active ingredient	Glibenclamide (Glyburide)
Form	Tablet (oral)
Pharmacological class	Oral Hypoglycemic Agent
Common use	Management of Type 2 diabetes mellitus
Origin	Synthetic

Diatab: A Synthetic Oral Hypoglycemic Agent

Diatab is a prescription-only medication whose active component, Glibenclamide (also known as Glyburide), defines it as an Oral Hypoglycemic Agent. This classification places it within the broader category of antidiabetic drugs administered by mouth to facilitate the reduction of elevated blood sugar levels. Glibenclamide is a synthetic compound that belongs specifically to the second-generation sulfonylurea class. This class distinction highlights its potency compared to older agents. Glibenclamide is utilized for controlling elevated blood sugar levels and serves as a tool for managing blood sugar. It is specifically designed for adults managing the chronic blood sugar imbalances characteristic of Type 2 diabetes mellitus.

Composition, Form, and General Function

The medicinal preparation is provided as a single-ingredient product in a tablet, a solid dosage form intended for the oral route of administration. The active substance, Glibenclamide, is combined with pharmaceutical solid excipients necessary for the tablet's structural integrity and consistent absorption. Glibenclamide functions as an insulin secretagogue; its primary and general purpose is to stimulate the beta-cells of the pancreas to release more of the body's native insulin into the bloodstream. As a sulfonylurea, the medication works by promoting insulin secretion from the pancreas, utilizing the body's existing mechanisms to process sugar. This direct mechanism of action distinguishes it from agents that primarily enhance insulin sensitivity. By augmenting this process, the compound supports the achievement of fundamental blood glucose management, which is the core therapeutic goal of this class of medication.

Regulatory References

What side effects are possible with Diatab?

Possible side effects and safety information

The official safety profile for Diatab, whose active ingredient is Glibenclamide, is defined by the central risk of Hypoglycemia, which is documented as potentially severe and prolonged. As an Oral Hypoglycemic Agent, this is the most critical metabolic adverse effect acknowledged by regulatory authorities. The adverse reactions are formally classified across several System-Organ Classes.

Documented Adverse Reactions and Systemic Effects

Adverse reactions listed in regulatory documents include effects on the Metabolism and Nutrition system, primarily hypoglycemia and the potential for hyponatremia. Gastrointestinal Disorders such as nausea, vomiting, heartburn, and metallic taste are also documented. Other possible effects involve the Hepatobiliary System (e.g., liver enzyme elevation, cholestatic jaundice) and rare but serious effects on the Blood and Lymphatic System (known as blood dyscrasias, including agranulocytosis).

Serious Adverse Reactions and Population Constraints

Regulatory sources specify several serious adverse reactions, including Severe and prolonged hypoglycemia, certain severe Blood Dyscrasias, severe Allergic Reactions (such as Stevens-Johnson syndrome), and documented concerns regarding increased cardiovascular mortality in this drug class. Safety constraints also apply to specific populations. Elderly, debilitated, or malnourished patients are recognized as being particularly susceptible to hypoglycemia. Furthermore, the risk of prolonged hypoglycemic reactions is increased in cases of severe renal or hepatic insufficiency. The medication is generally contraindicated during pregnancy and not recommended during lactation. The official label also notes that skin hypersensitivity reactions may typically occur within the first six weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The principal manifestation of Glibenclamide overdose is severe and prolonged hypoglycemia (low blood sugar), which is officially documented as potentially life-threatening. Overdose symptoms include autonomic signs such as sweating, clammy skin, and rapid heartbeat, alongside CNS signs like confusion, slurred speech, seizures, and coma. The clinical presentation of a severe event may resemble a stroke.

Due to the risk of permanent brain damage or death, regulatory guidance mandates that a patient seek immediate medical attention for any severe or protracted hypoglycemic episode. Emergency services must be called immediately if the person is unconscious, convulsing, or cannot be awakened.

The official management protocol requires hospital monitoring for a minimum of 12 to 24 hours because of the risk of recurrent hypoglycemia. The immediate supportive measure described in official documents is the administration of intravenous glucose (IV dextrose). Elderly patients and those with hepatic or renal insufficiency are noted to be particularly susceptible to these severe, prolonged reactions. Furthermore, in children, ingestion of even a single tablet is documented as capable of causing life-threatening hypoglycemia.

Therapeutic Uses of Diatab

What Diatab Treats: Main Uses and Benefits

Diatab is used for the chronic management of Type 2 diabetes mellitus in adults, and is generally applied when the condition is not adequately controlled by lifestyle measures alone. The medication is commonly applied as an adjunct to diet and exercise to help improve blood sugar management. The therapy is relevant in clinical settings marked by systemic imbalance, a condition where the body’s regulatory systems are insufficient, requiring pharmacological assistance.

Diatab plays a role in managing the resulting symptoms that interfere with daily functioning and helps address the persistent high blood sugar that is a feature of the disease. The long-term therapeutic focus is on mitigating the risk factors associated with chronic hyperglycemia. Through support for consistent blood sugar management, the therapy may assist with reducing the likelihood of conditions characterized by heightened symptoms affecting the heart, kidneys, nerves, and other vital systems. The use of the medication is relevant for easing the overall burden of symptoms related to systemic imbalance, assisting with maintaining functional stability and supporting general well-being during the phases of chronic management.

Quick Fact: Supportive Role in Systemic Imbalance
Primary Use Context: Used when Type 2 diabetes is not adequately controlled by lifestyle alone.
Symptom Focus: Helps manage symptoms related to systemic imbalance that often accompany Type 2 diabetes.
Patient Benefit: Contributes to easing the overall symptom load and assists with maintaining functional stability.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Diatab (Glibenclamide)

The use of Diatab is officially established for adults managing Type 2 diabetes mellitus. Regulatory documents strictly define the boundaries for use, classifying populations into allowed, contraindicated, and restricted groups based on age, physiological status, and underlying conditions.

Absolute Contraindications Diatab is strictly contraindicated and must not be used by patients with known hypersensitivity to Glibenclamide, Type 1 diabetes mellitus, or diabetic ketoacidosis. A mandatory prohibition also applies to patients concurrently treated with the medication Bosentan.

Age and Physiological Restrictions The medicine is not established and not recommended for the pediatric population. Due to an increased susceptibility to severe, prolonged hypoglycemia, elderly patients and individuals with severe hepatic or renal insufficiency require caution. Use is contraindicated during pregnancy and breastfeeding according to many global regulatory labels. Caution is further required for patients with G6PD deficiency or conditions like adrenal or pituitary insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Diatab, whose active ingredient is Glibenclamide, through classifications based on formal prohibitions, pharmacokinetic changes, and pharmacodynamic effects.

Interaction-Related Restrictions

Classification	Interacting Substance	Official Regulatory Outcome
Contraindicated Combination	Bosentan	Concomitant use is prohibited due to an increased risk of elevated liver enzymes [FDA Label].
Timing Separation Rule	Colesevelam	Diatab must be administered at least 4 hours prior to Colesevelam to minimize the documented reduction in its systemic exposure [DailyMed].
Substance Interaction	Alcohol (Ethanol)	Acute or chronic alcohol intake may unpredictably potentiate or weaken the blood-glucose-lowering action [HPRA SmPC].

Exposure and Effect Modification

Interactions are formally documented as leading to either potentiation (increased effect) or weakening (decreased effect) of the blood sugar control:

Potentiation of the hypoglycemic action is documented with numerous medicinal products, including Azole Antifungals (such as oral Miconazole), Beta-blockers, NSAIDs, and MAO Inhibitors [FDA Label]. Beta-blockers may also mask the typical signs of hypoglycemia [HPRA SmPC].
Weakening of the blood-glucose-lowering effect is documented with agents such as Corticosteroids, Thiazide Diuretics, and Estrogens [FDA Label].
Certain agents, like Rifampicin, are documented to weaken the effect through the induction of metabolic enzymes CYP2C9 and CYP3A4 [HPRA SmPC].
Glibenclamide is documented to increase the plasma concentration of Cyclosporine, which may lead to heightened toxicity for that co-administered medicine [HPRA SmPC].

Population-Specific Interaction Notes

The risk of serious hypoglycemic reactions resulting from co-administration with potentiating agents is noted to be heightened in patients with Hepatic or Renal Impairment due to the potential for elevated Glibenclamide drug levels [FDA Label]. This consideration is also documented for elderly patients (65 years and older).

Mechanism of Action

Mechanism of Action: Non-Systemic Luminal Adsorption

Diatab's action is confined to the gastrointestinal lumen and is strictly non-systemic. The core mechanism involves the physicochemical binding (adsorption) of aqueous fluid and luminal irritants onto the vast surface area of the adsorbent agents (e.g., Kaolin or Attapulgite). This physical interaction reduces the concentration of free water available for transit within the large intestine.

This binding initiates a mechanistic cascade that increases the overall bulk and viscosity of the intestinal contents. The change in the composition of the luminal mass affects the mass transfer equilibrium of water across the intestinal wall, resulting in an increase in the fecal solids-to-liquid ratio.

Furthermore, the physical sequestration of bacterial toxins and other irritants by the adsorbent forms a local physical layer on the intestinal mucosa. This modulates the chemical and physical environment at the epithelial surface, thereby affecting localized fluid exchange processes.

Dosage and Administration Information

The administration of Diatab is restricted to the oral route, consistent with its formulation as a tablet. The medicine is generally used for the chronic, long-term management of Type 2 diabetes mellitus. A key principle for its use is synchronization with the daily eating schedule: the tablet is taken with breakfast or the first main meal of the day, and it must be swallowed whole with liquid.

The initial dosage for the standard tablet is typically 2.5 mg to 5 mg administered once daily. The dose is subject to adjustment, or titration, at intervals of at least one week, based on monitoring, with increases limited to a range of 1.25 mg to 2.5 mg. The maximum recommended daily dosage is 20 mg. Daily doses exceeding 10 mg are generally administered in two divided doses to maintain consistency.

For older adults and patients with impaired hepatic or renal function, common practice involves the use of a lower, more conservative initial dose, often starting at 1.25 mg or 2.5 mg once daily. If a scheduled dose is missed, guidelines state that the dose should not be doubled to compensate; the regular schedule should be resumed, skipping the missed amount if the next dose is due shortly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diatab

Evidence for Use in Chronic Management of Type 2 Diabetes Mellitus

Diatab (Glibenclamide) was studied for the long-term management of Type 2 diabetes in adults, including newly diagnosed patients. The evidence base includes long-term, large-scale randomized controlled trials (RCTs) and systematic reviews that compared Glibenclamide-based management to conventional treatment or other active agents. Research primarily examined the effects of these strategies on biomarkers of glycemic control, such as the HbA1c test, and monitored the progression of long-term health issues. The research describes patterns observed where intensive management was associated with long-term measurements of microvascular outcomes (affecting eyes and kidneys) compared to standard approaches. However, long-term outcomes are not fully established across all clinical endpoints.

Evidence in Specific Patient Groups and Remaining Uncertainty

Specialized studies were conducted to explore the use of Glibenclamide in the pregnancy-related population (Gestational Diabetes Mellitus, GDM), typically comparing it to insulin or metformin. Studies reported that Glibenclamide was associated with changes in maternal blood sugar measurements comparable to other treatments. However, the findings were mixed regarding neonatal outcomes, such as the incidence of fetal macrosomia or neonatal hypoglycemia. This suggests that the comparative evidence for GDM lacks consistent findings.

For most populations, evidence for Glibenclamide includes research derived from settings with varying symptom burdens over decades, with some studies involving post-trial monitoring that followed participants for ten or more years. Scientific literature points to areas where comparative evidence is still lacking, particularly for large-scale RCTs that directly compare Glibenclamide to the newest classes of Type 2 diabetes medications. Studies also describe patterns where the incidence of severe hypoglycemia (very low blood sugar) was reported more frequently in patients receiving Glibenclamide treatment arms compared to conventional or control groups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Diatab (FAQ)

Q: Is Diatab considered a strong medicine?

A: Diatab is an oral hypoglycemic agent and is classified in regulatory documents as a second-generation sulfonylurea. This drug class is noted in pharmacological literature for having increased potency compared to earlier generations of similar medicines.

Q: Does Diatab work right away, or does it take time?

A: According to the official product information, after taking a tablet by mouth, the active drug reaches its highest concentration in the bloodstream in approximately 1.5 hours. This indicates the typical time for the drug's concentration to peak, but achieving consistent blood sugar control usually requires ongoing use as directed by a healthcare provider.

Q: How long does the effect of Diatab usually last?

A: Studies on the drug’s elimination indicate that its terminal half-life (the time it takes for half the drug to be eliminated from the body) is approximately 10 to 15 hours. This longer duration of action is a factor that supports once or twice-daily administration regimens.

Q: What are the signs of a serious problem with Diatab?

A: The most critical risk documented in the official safety profile is severe or prolonged hypoglycemia (very low blood sugar). Signs of this serious problem may include sudden feelings of being shaky, anxious, dizzy, or having heart palpitations.

Q: Can taking Diatab make you gain weight?

A: Weight gain has been listed as a documented side effect for Glibenclamide in patient information leaflets in some regions. This outcome is described in the general adverse event section of the medication’s profile.

Q: Is there a generic version of Diatab available?

A: Yes, the active ingredient in Diatab is Glibenclamide, which is also known as Glyburide (USAN). This active component is widely available globally under its generic name.

Q: Can you take Diatab with pain relievers like Tylenol or Advil?

A: Official information notes a need for caution when Diatab is used alongside NSAIDs (like Ibuprofen/Advil) because they may potentially increase the blood-sugar-lowering effect of Diatab. The interaction profile specifically documented by regulators does not always include Acetaminophen (Tylenol).

Q: Can Diatab be used by people with high blood pressure?

A: The drug is not strictly contraindicated in people with high blood pressure, but one clinical study reported that Glibenclamide was associated with worsening blood pressure control in subjects who also had hypertension. The official documentation emphasizes the need for close monitoring when used by individuals with co-occurring conditions.

Q: Is Diatab safe for older adults (seniors)?

A: Regulatory documents specify that Diatab is associated with a higher risk of severe and prolonged hypoglycemia in older adults (65 years and older). Because of this increased risk, regulatory documents state that a lower initial dose and caution are specified for this population.

Q: Is Diatab known to cause long-term side effects?

A: Official overviews of studies indicate long-term concerns for this drug class. This includes a documented risk of increased cardiovascular mortality compared to placebo, a serious finding described in the context of clinical trials.

Q: Can men and women use Diatab for the same reasons?

A: Yes, regulatory documents indicate the medicine is approved for the management of Type 2 diabetes mellitus in adults generally. The indication is for Type 2 diabetes mellitus in adults generally.

Q: Is Diatab a controlled substance?

A: No. Official regulatory scheduling confirms that Diatab is a prescription-only (Rx-only) medication. It is not classified as a federally scheduled controlled substance.

Q: How do I know if Diatab is actually helping me?

A: Official patient instructions advise that close blood glucose monitoring is used to check the drug’s assistance with blood sugar management, as directed by a healthcare provider.

Q: Does Diatab affect mood or energy levels?

A: The drug's central risk is hypoglycemia (very low blood sugar), and official safety documents list symptoms that can affect your mental state. These symptoms include feeling anxious and experiencing unusual tiredness or weakness.

Q: Are there different strengths or types of Diatab available?

A: Yes. Regulatory documents detail that the drug is available in various strengths to allow for precise dosing adjustments, also known as titration, which is part of the regimen for managing Type 2 diabetes.

Q: What does the research say about Diatab's effectiveness compared to no treatment?

A: Studies generally suggest that sulfonylurea drugs are effective compared to no treatment (placebo). They have been shown to reduce long-term blood sugar biomarkers ( HbA1c) by approximately 1% to 2% in clinical settings.

Q: Can Diatab interfere with birth control pills?

A: The official regulatory interaction profile lists that Estrogens (a component found in many oral contraceptives) may weaken the blood-glucose-lowering effect of Diatab. Due to this potential interaction, blood sugar monitoring may be part of the care plan.

Q: What are the restrictions on driving while using Diatab?

A: Official warnings indicate that the ability to drive or operate machinery may be impaired for patients using Diatab. This caution is relevant because the medicine carries the risk of hypoglycemia (low blood sugar).

Q: Are there common reasons why a doctor might not prescribe Diatab?

A: Yes, official eligibility criteria prohibit use in certain conditions. A doctor may avoid prescribing Diatab if the patient has Type 1 diabetes, diabetic ketoacidosis, or is prone to severe, prolonged hypoglycemia.

Q: What does 'contraindicated' mean in the context of Diatab use?

A: A contraindication is a strict statement from health authorities that the medication must not be used under certain conditions, such as Type 1 diabetes. This is because the risk of harm in that situation outweighs any potential benefit.

Q: How long has Diatab been available to the public?

A: The active ingredient, Glibenclamide, is a second-generation sulfonylurea that has been available for decades. It was registered in some jurisdictions as early as the 1990s, making it a medication with a long history of use.

Q: What should I do if I accidentally take two doses of Diatab close together?

A: Official patient information explicitly warns never to double the dose to compensate for a missed one, indicating that excessive dosing is a serious concern. An accidental double dose is considered a potentially serious event due to the risk of severe hypoglycemia.

How should Diatab be stored and disposed of?

How to Store and Dispose of Diatab (Glibenclamide)

Diatab tablets must be stored according to specific regulatory requirements to maintain product stability and quality.

Storage Requirements

The medication should be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The tablets must be protected from light and kept away from excessive heat and moisture. It is mandatory to dispense and store the product in a tight, light-resistant container that is kept tightly closed.

Disposal and Safety

For safety, Diatab must be stored out of the reach of children. To dispose of unused or expired tablets, the official guideline is to use a drug take-back program. If a take-back option is unavailable, the medication can be mixed with an undesirable substance and sealed in a container before disposal in the household trash, following the instructions from the FDA.

Diatab